Centre Hospitalier Bretagne Atlantique
- Address
- lock Available on a paid plan
Infectious Diseases and Respiratory Care
Clinical research at Centre Hospitalier Bretagne Atlantique focuses strongly on bacterial infections and respiratory tract diseases, especially severe community-acquired pneumonia and severe community-acquired bacterial pneumonia. These studies are designed to test new add-on therapies, compare antimicrobial strategies, and improve recovery and safety in seriously ill patients.
- Evaluating a new treatment approach for severe pneumonia and its impact on clinical recovery.
- Assessing safety and tolerability of therapies used in patients with serious respiratory infection.
- Comparing narrow-spectrum and broad-spectrum antibiotics in older adults hospitalized with community-acquired pneumonia.
The work reflects a practical effort to improve outcomes in infection care while supporting more targeted and effective use of treatment.
Critical Care and Ventilation Support
The site’s Service de soins intensifs also supports research in respiratory failure and intensive care management, with studies aimed at helping patients come off advanced breathing support more successfully. This area of research focuses on improving treatment pathways for people with de novo acute respiratory failure and related critical conditions.
- Testing a structured weaning approach for patients receiving high-flow nasal oxygen therapy.
- Improving the chance of successful liberation from respiratory support in intensive care settings.
- Studying care strategies for acute respiratory failure in severely ill patients.
These trials aim to make critical care more effective, safer, and easier to manage for both patients and clinical teams.
Digestive System and Gastrointestinal Oncology
Research in digestive system diseases and digestive system and oral physiological phenomena includes studies in colon carcinoma and small bowel adenocarcinoma. The goal is to better understand treatment effectiveness and long-term disease control in gastrointestinal cancers, including approaches guided by circulating tumor DNA.
- Evaluating treatment strategies for small bowel adenocarcinoma to improve disease control.
- Studying whether ctDNA can help guide post-surgery cancer treatment decisions.
- Assessing the percentage of patients alive without progression over time.
This research supports more personalized cancer care by refining how treatment response and recurrence risk are monitored.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 17 therapeutic areas and 15 of 114 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 99 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 22 by active trials.
lock +21 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +12 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centre Hospitalier Bretagne Atlantique
lock Showing 1 of 56 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) [frontMIND] | Incyte Corp. | Phase III | Not Recruiting | Apr 2021 | — |
IMP list
lock Showing 1 of 114 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Lenalidomide | 9 | Unknown | 2019-10-07 | 2026-02-25 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.